Effects of Efonidipine, an L- And T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients with Mild to Severe Hypertension: An Uncontrolled, Open-Label Pilot Study

Current Therapeutic Research - Clinical and Experimental

Volumn 64, Issue 9, 2003, Pages 707-714

  Shimizu, Mitsuyuki ^a,b   Ogawa, Kazuhiko ^a   Sasaki, Hideki ^a   Uehara, Yoshiki ^a   Otsuka, Yumi ^a   Okumura, Hiroyuki ^a   Kusaka, Masafumi ^a   Hasuda, Toshio ^a   Yamada, Taku ^a   Mochizuki, Seibu ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Calcium channel blocker; Efonidipine; Heart rate; Hypertension; Reflex tachycardia; T type calcium channel

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; DIHYDROPYRIDINE DERIVATIVE; EFONIDIPINE; FELODIPINE; MANIDIPINE; MEPIRODIPINE; NIFEDIPINE;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; TACHYCARDIA;

EID: 1642479992     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2003.11.004     Document Type: Article

References (19)

1. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published correction appears in JAMA. 2003;289:178]. JAMA. 2002;288:2981-2997.
2. Liu L, Wang JG, Gong L, et al, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
3. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
4. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al, the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684.
5. The Israeli SPRINT Study Group. Secondary Prevention Reinf arction Israeli Nifedipine Trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
6. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
7. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
8. Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial (SPRINT) 2 study. Arch Intern Med. 1993;153:345-353.
9. Bühler FR. Cardiovascular care with the new T-type calcium channel antagonist: Possible role of attendant sympathetic nervous system inhibition. J Hypertens Suppl. 1997;15:S3-S7.
10. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J. 1993;125:1148-1154.
11. Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: A risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585-592.
12. Palatini P, Julius S. The physiological determinants and risk correlations of elevated heart rate. Am J Hypertens. 1999;12:3S-8S.
13. 2+ currents by efonidipine: Possible mechanism for its chronotropic effect. Eur J Pharmacol. 1998;349:351-357.
14. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385-392.
15. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol. 1990;66:779-785.
16. Riley J, Wilton LV, Shakir SA. A post-marketing observational study to assess the safety of mibefradil in the community in England. Int J Clin Pharmacol Ther. 2002;40: 241-248.
17. Glasser SP. The relevance of T-type calcium antagonists: A profile of mibefradil. J Clin Pharmacol. 1998;38:659-669.
18. Massie BM. Mibefradil, a T-type channel-selective calcium antagonist: Clinical trials in chronic stable angina pectoris. Am J Hypertens. 1998;11:95S-102S.
19. Clozel JP, Ertel EA, Ertel SI. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl. 1997;15:S17-S25.